Abbott pulls briakinumab filings in the US and EU
This article was originally published in Scrip
Abbott is looking at a possible several-year delay for its new Crohn's disease therapy briakinumab, after withdrawing its approval applications for the product in both the US and the EU.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.